Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw
Primary Purpose
Blood Loss, Healthy
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
CM-1500
Sponsored by

About this trial
This is an interventional diagnostic trial for Blood Loss focused on measuring blood, loss, healthy, volume, To evaluate the ability of the Zynex BVM to non-invasively detect blood loss in healthy subjects during a blood draw.
Eligibility Criteria
Inclusion Criteria:
- Written informed consent
- Male, 18-65 years of age
- Subject is suitable for a blood draw of a pint of blood
- Weighs at least 110 pounds
Exclusion Criteria:
- Subject has a heart condition that may interfere with the Zynex CM-1500
- Subject has unstable or untreated heart disease
- Subject has been diagnosed with chronic fatigue syndrome
- Subject is taking coumadin (warfarin), heparin, or other prescription blood thinners for at least 7 days prior to blood draw
- Subject donated blood within 8 weeks prior to blood draw
- Subject has high or low blood pressure on the day of blood draw
- Subject hemoglobin < 12.5 g/dL
Sites / Locations
- Rocky Mountain Urgent Care
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Blood Draw
Arm Description
Outcomes
Primary Outcome Measures
Detect change in blood volume during blood draw
Secondary Outcome Measures
Detect insidious bleeding
Full Information
NCT ID
NCT01646060
First Posted
November 28, 2011
Last Updated
July 17, 2012
Sponsor
Zynex Monitoring Solutions
1. Study Identification
Unique Protocol Identification Number
NCT01646060
Brief Title
Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw
Official Title
Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw
Study Type
Interventional
2. Study Status
Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zynex Monitoring Solutions
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Zynex's blood volume monitor (BVM) is a non-invasive monitoring device to monitor blood volume and blood loss of a patient during surgery, post operatively and/or in recovery. This monitoring device will identify baseline blood volume and relative changes in blood volume using a specific algorithm to compare and review data already monitored during surgery, displaying blood volume and blood loss in real-time.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Loss, Healthy
Keywords
blood, loss, healthy, volume, To evaluate the ability of the Zynex BVM to non-invasively detect blood loss in healthy subjects during a blood draw.
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Blood Draw
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
CM-1500
Intervention Description
Blood Volume Monitor
Primary Outcome Measure Information:
Title
Detect change in blood volume during blood draw
Time Frame
15-30 minutes
Secondary Outcome Measure Information:
Title
Detect insidious bleeding
Time Frame
15-30 minutes
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Written informed consent
Male, 18-65 years of age
Subject is suitable for a blood draw of a pint of blood
Weighs at least 110 pounds
Exclusion Criteria:
Subject has a heart condition that may interfere with the Zynex CM-1500
Subject has unstable or untreated heart disease
Subject has been diagnosed with chronic fatigue syndrome
Subject is taking coumadin (warfarin), heparin, or other prescription blood thinners for at least 7 days prior to blood draw
Subject donated blood within 8 weeks prior to blood draw
Subject has high or low blood pressure on the day of blood draw
Subject hemoglobin < 12.5 g/dL
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nathaniel Moore, MD
Organizational Affiliation
Rocky Mountain Urgent Care
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rocky Mountain Urgent Care
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80012
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw
We'll reach out to this number within 24 hrs